Announcements
Projects
Orgs
Project Post
Articles 13
Votes 0
Merck.com
Articles
13
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com
24d
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia - Merck.com
24d
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline - Merck
>1y
The impact of RSV: a father’s story and call for prevention - Merck
>1y
Merck to Acquire Caraway Therapeutics, Inc. - Merck
>1y
Merck Announces Third-Quarter 2023 Financial Results - Merck
>1y